Tudor Christiane Silke, Bruns Heiko, Daniel Christoph, Distel Luitpold Valentin, Hartmann Arndt, Gerbitz Armin, Buettner Maike Julia
Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Department of Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, University Hospital, 91054 Erlangen, Germany.
PLoS One. 2014 Dec 3;9(12):e114345. doi: 10.1371/journal.pone.0114345. eCollection 2014.
BACKGROUND: The inflammatory infiltrate plays a pivotal role in classical Hodgkin lymphoma (cHL). Here, we focussed on the role of macrophages (MΦ) and dendritic cells (DC). METHODS: MΦ and DC infiltration was investigated in 106 cHL specimens using immunohistochemistry and cytokine expression was analyzed in a subset by real-time PCR. Human peripheral blood-derived monocytes, DC, MΦ stimulated with GM-CSF (MΦGM-CSF, pro-inflammatory MΦ-1-model) or M-CSF (MΦM-CSF, immunomodulatory MΦ-2-model) were incubated with cHL cell line (L1236, HDLM2) supernatants (SN). DC maturation or MΦ polarization were investigated by flow cytometry. Furthermore, the impact of DC or MΦ on cHL cell proliferation was analyzed by BrdU/CFSE assay. RESULTS: In cHL tissues mature myeloid (m)DC and MΦ predominated. High numbers of CD83+ mDC and low numbers of CD163+ MΦ were associated with improved disease specific survival. In numerous cHL specimens increased levels of both pro- and anti-inflammatory cytokines and of IL13 and GM-CSF were observed compared to reactive lymphadenopathies. Maturation of DC and induction and maintenance of an immunomodulatory MΦ phenotype were promoted by SN derived from cHL cell lines. TNFα neutralization in SN resulted in a significant inhibition of mDC maturation. DC and pro-inflammatory MΦ inhibited the proliferation of cHL cells. CONCLUSION: Adopting an immunomodulatory phenotype is a potential mechanism for how MΦ promote immune evasion in cHL. Mature DC, in contrast, might participate in antitumoral immunity.
Eur J Immunol. 1997-2
J Immunol. 1998-5-1
J Immunol Methods. 2011-10-29
Clin Cancer Res. 2012-12-5
Clin Exp Med. 2024-1-29
Chin Med J (Engl). 2024-4-5
Biomedicines. 2022-3-1
Cancers (Basel). 2022-3-13
Cancers (Basel). 2022-3-7
Blood Adv. 2021-10-26
J Environ Pathol Toxicol Oncol. 2013
Clin Cancer Res. 2012-12-5
Clin Chim Acta. 2012-1-27